UBS Group
CLB icon

UBS Group’s Core Laboratories CLB Stock Holding History

UBS Group’s Portfolio CLB Stock Details CLB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-12,100
Closed -$1.26M – 8516
2015
Q1 		$1.26M Buy
12,100
+12,000
+12,000% +$1.28M ﹤0.01% 3359
2014
Q4 		$12K Buy
+100
New +$13.1K ﹤0.01% 8212

Other funds holding CLB

AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $5.91B AUM 53.97% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CAMG
CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

UBS Group's CLB Position: Q2 2026 in Review

UBS Group increased its Core Laboratories (CLB) stake by 7% in Q2 2026, buying an estimated $430K and bringing the position to 461,777 shares worth $5.38M. The position accounts for ﹤0.01% of the portfolio, ranked #4101.

UBS Group first reported a position in CLB in Q4 2014 and has held it in 47 quarters since. The position peaked at $7.25M in Q1 2026. 186 funds tracked by Wall St. Rank hold CLB as of Q2 2026.

  • UBS Group held 461,777 shares of Core Laboratories worth $5.38M as of Q2 2026.
  • UBS Group bought 30,124 Core Laboratories shares in Q2 2026, an estimated $430K.
  • Core Laboratories made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4101 holding.
  • UBS Group first reported a position in Core Laboratories in Q4 2014 and has held it in 47 quarters since.
  • UBS Group's Core Laboratories position peaked at $7.25M in Q1 2026.
  • 186 funds tracked by Wall St. Rank held Core Laboratories as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.